WASHINGTON - Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the U.S. Food and Drug Administration said on Monday.
Remember that Avastin is the anti VEGF antibody. Stay tuned if anything else is posted in the science journals that isnt available to the public, it will be here. Genentech (NYSW: DNA) finished up today 1.4% at 79.66 in average trading.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment